Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and blood

Figures & data

Table 1. Amount of ingredients required for the preparation of DLX-NLC.

Ingredients	Concentration
DLX (g/l)	2
Lipids (GMS and capryol PGMC) (% w/w)	2
Ratio of liquid lipid to total lipid	0.94:1
Pluronic F-68 (Poloxamer) (% w/w)	1.5
Sodium taurocholate (% w/w)	0.5
Water	q.s. (up to 100%)

Figure 1. Schematic presentation for in vivo nasal infusion studies.

Figure 2. Amount of DLX absorbed into the body of rat after intranasal infusion of DLX solution and DLX-NLC dispersed in water.

Figure 3. Rate of absorption of DLX in rats after intranasal infusion of DLX solution and DLX-NLC dispersed in water.

Table 2. Concentration of DLX in brain and blood after intranasal infusion studies.

	Concentration (n = 3)
Formulation	Brain (µg/g)	Plasma (µg/ml)
DLX-NLC	228.8874 ± 83.72	1869.247 ± 112.61
DLX solution	95.75 ± 24.28	728.34 ± 63.52
Permeation enhancement (NLC/DLX)	2.390	2.566